Zydelig Takes Major Hit, But Not A Big Blow For Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA joins European regulators in warning about fatalities in trials of Gilead’s PI3 kinase inhibitor Zydelig (idelalisib), news that is a blow for a drug that had yet to get off the ground.